P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Paul G. Richardson,Constantine S. Mitsiades,Jacob P. Laubach,Robert L. Schlossman,Irene M. Ghobrial,Teru Hideshima,Nikhil C. Munshi,Kenneth C. Anderson +7 more
TL;DR: Emerging evidence supports the ongoing investigation of lenalidomide in combination with low-dose dexamethasone, and in other combinations including bortezomib, for use both in relapsed, refractory, and newly diagnosed MM.
Journal ArticleDOI
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET:
T. Lee Collier,T. Lee Collier,Kevin P. Maresca,Marc D. Normandin,Paul G. Richardson,Timothy J. McCarthy,Steven H. Liang,Rikki N. Waterhouse,Neil Vasdev +8 more
TL;DR: The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique 11C and 18F-labeling strategies to synthesize isotopologs of lorlatinib which is undergoing phase III clinical trial investigations for treatment of non-small-cell lung cancers with specific molecular alterations.
Journal ArticleDOI
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.
Andrzej Jakubowiak,Donna E. Reece,Craig C. Hofmeister,Sagar Lonial,Todd M. Zimmerman,Erica L. Campagnaro,Robert L. Schlossman,Jacob P. Laubach,Noopur Raje,Tara B. Anderson,Kent A. Griffith,Melissa A. Hill,Colleen K. Harvey,Akari M. Dollard,Sandra Wear,Jennifer Barrickman,Craig L. Tendler,Dixie-Lee Esseltine,Susan L. Kelley,Mark S. Kaminski,Kenneth C. Anderson,Paul G. Richardson +21 more
TL;DR: The 4-drug RVDD regimen of lenalidomide (Revlimid®, Len), Bz (Velcade), pegylated liposomal doxorubicin (Doxil®, PLD), and dexamethasone (Dex), which demonstrates high activity in newly diagnosed MM, is developed and results are presented.
Journal ArticleDOI
Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Parameswaran Hari,Kenneth H. Shain,Peter M. Voorhees,Nashat Y. Gabrail,Muneer H. Abidi,Jeffrey A. Zonder,Ralph V. Boccia,Paul G. Richardson,Linda Neuman,Sandra Dixon,Claudia Paba Prada +10 more
TL;DR: This multicenter, single arm phase 1b/2 study evaluates the safety and tolerability of OPZ with dexamethasone (DEX) in patients with relapsed and/or refractory MM to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of OPz with DEX and to evaluate safety and tolerateability.
Journal ArticleDOI
Studies on the Regioselective Nucleophilic Aromatic Substitution (SNAr) Reaction of 2-Substituted 3,5-Dichloropyrazines
Stephanie Scales,Sarah Johnson,Qiyue Hu,Quyen-Quyen T. Do,Paul G. Richardson,Fen Wang,John F. Braganza,Shijian Ren,Yadong Wan,Baojiang Zheng,Darius J. Faizi,Indrawan James Mcalpine +11 more
TL;DR: This study revealed that when the 2-position of the pyrazine was occupied with an electron-withdrawing group (EWG), nucleophilic attack occurred preferentially at the 5-position.